









Markets
/
Stocks
/
nasdaq-irix
/

IRIDEX Corp

IRIX

1.050USD

+0.010+0.96%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

17.66MMarket Cap

LossP/E TTM



IRIDEX Corp

1.050

+0.010+0.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of IRIDEX Corp

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IRIDEX Corp's Score

Industry at a Glance

Industry Ranking

154 / 210

Overall Ranking

417 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

IRIDEX Corp Highlights

StrengthsRisks

IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.

Growing

The company is in a growing phase, with the latest annual income totaling USD 48.67M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 48.67M.

Fairly Valued

The company’s latest PE is -3.21, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.68M shares, decreasing 13.62% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 585.81K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.39.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 13.57M, representing a year-over-year increase of 7.44%, while its net profit experienced a year-over-year increase of 62.90%.

Score

Industry at a Glance

Previous score

6.29

Change



Financials

6.18

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

5.83

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.76

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.20

Key Metrics

Free cash flow

No Data

IRIDEX Corp's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.37, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -3.21, which is -54.54% below the recent high of -1.46 and -112.03% above the recent low of -6.80.

Score

Industry at a Glance

Previous score

8.37

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 154/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Healthcare Equipment & Supplies industry's average is 7.74.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.07, which is lower than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 1.13 and the support level at 0.98, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.48

Change

-0.41

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.011

Neutral

RSI(14)

43.272

Neutral

STOCH(KDJ)(9,3,3)

44.709

Neutral

ATR(14)

0.039

High Vlolatility

CCI(14)

-39.743

Neutral

Williams %R

57.531

Sell

TRIX(12,20)

-0.414

Sell

StochRSI(14)

22.007

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.053

Sell

MA10

1.055

Sell

MA20

1.058

Sell

MA50

1.171

Sell

MA100

1.160

Sell

MA200

1.171

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 15.76%, representing a quarter-over-quarter decrease of 65.09%. The largest institutional shareholder is The Vanguard, holding a total of 585.81K shares, representing 3.45% of shares outstanding, with 2.22% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Topcon Corp

1.62M

+0.37%

Stanley Manne Trust

1.07M

Paragon JV Partners, LLC

1.00M

The Vanguard Group, Inc.

Star Investors

585.81K

-1.51%

Roland (Brent Alexander)

461.71K

Renaissance Technologies LLC

Star Investors

378.76K

-0.11%

Moore (William M)

300.00K

+4.18%

Roland Family Support Trust

223.69K

AMH Equity, Ltd.

190.00K

-63.36%

Roland (Glenn Cuthbert)

181.60K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.56, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.